Tenderwize
Wróć do wyszukiwania

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2026 · 65 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glyceroltrinitrat (ATC-Code nach WHO: C05AE01)

50/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

40 / 100

Czynniki ryzyka

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat (ATC: C05AE01)
  • Open House model: any eligible pharmaceutical entrepreneur can participate
Pokaż pełne podsumowanie

Non-exclusive pharmaceutical discount agreements (Rabattvereinbarungen) under §130a(8) SGB V for the active ingredient Glyceroltrinitrat (ATC: C05AE01) via an Open House model. Buyer is AOK PLUS for the regions of Saxony and Thuringia, Germany. The process is open to all eligible pharmaceutical entrepreneurs; no competitive award, all qualified participants are accepted. Contract ends 31 October 2026. Purchase volume and value are unknown. The notice clarifies this is not a public procurement subject to EU procurement law.

Ryzyka

Purchase volume is unpredictable, dependent on prescription behavior and patient numbers; no minimum quantity guarantee...

Buyer may terminate the Open House and existing agreements if exclusive discount agreements are signed (typically 8-12...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
  • No connections to Russia per EU sanctions (Regulation 833/2014)

Administrative

  • Complete and submit documents via DTVP portal

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No specific award criteria disclosed; this is a non-competitive Open House model.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement for Glyceroltrinitrat (ATC: C05AE01)

Conclusion of non-exclusive discount agreements for pharmaceutical products with active ingredient Glyceroltrinitrat. Open House model: all interested pharmaceutical companies meeting conditions can participate; no individual negotiations; no exclusivity; no minimum purchase quantities; rolling submissions until final deadline.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jun 2025 - Oct 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

No specific award criteria disclosed; this is a non-competitive Open House model.

Termin

Deadline Oct 31, 2026

Szczegóły zamówienia

Data publikacji
29 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
346931-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3